UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $92.02 and traded as high as $98.33. UCB shares last traded at $98.04, with a volume of 108,542 shares trading hands.
UCB Stock Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company’s 50 day moving average is $92.02 and its 200-day moving average is $80.32.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- What is a Low P/E Ratio and What Does it Tell Investors?
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- EV Stocks and How to Profit from Them
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
